ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Trends and risk factors associated with hepatitis A severity and mortality in French hospitals: a national population-based study, 2013 to 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDAs hepatitis A (HA) incidence declines in Europe and HA virus infections occur later in life, severe disease frequency may increase.AIMAmong patients hospitalised for HA in France during 2013-2024, we investigated disease severity and mortality associated-risk factors and temporal trends.METHODSInternational Classification of Diseases, 10th Revision codes B150 or B159 as primary discharge diagnosis enabled identifying HA cases from the National Discharge Data Set. Risk factors for severity (hepatic and/or extrahepatic organ failure within 12 weeks post-admission) and mortality were assessed using adjusted odds ratios in original and propensity-matched samples. Trends were determined across five periods covering an HA epidemic in 2017 and the COVID-19 pandemic, with 2013-2016 as reference.RESULTSAmong 7,923 cases (60.6% male, 39.4% female; median age: 30 years), 28.7% (n = 2,277) developed severe HA, and 1.30% (n = 103) died. Severe HA was associated with older age (+ 15% per decade over 30 years, p < 0.001), male sex (+ 38%, p < 0.001), smoking (+ 23%, p = 0.031), risk factors for chronic liver disease (+ 29%, p = 0.041), and cirrhosis (+ 40%, p = 0.054). Mortality was associated with cirrhosis (2.90-fold increase, p = 0.004), Charlson Comorbidity Index (CCI) ≥ 3 (12.3-fold increase, p < 0.001), and modestly with age (+ 24%, p = 0.005), reaching + 90% (p < 0.001) in models without CCI, indicating a considerable comorbidity effect. From 2013-2016, severe HA and HA-related death risks respectively increased 57% (p < 0.001) and 1.96-fold (p = 0.016) in 2021-2024.CONCLUSIONSSevere HA frequency and mortality increased in French hospitals since 2013. Age and male sex were associated with severe disease, and high CCI with mortality. A more extensive, or even universal, vaccination policy could be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.